CR20170249A - Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas - Google Patents
Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadasInfo
- Publication number
- CR20170249A CR20170249A CR20170249A CR20170249A CR20170249A CR 20170249 A CR20170249 A CR 20170249A CR 20170249 A CR20170249 A CR 20170249A CR 20170249 A CR20170249 A CR 20170249A CR 20170249 A CR20170249 A CR 20170249A
- Authority
- CR
- Costa Rica
- Prior art keywords
- solid state
- forms
- pirrolidinones
- fusioned
- heteroaromatic
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 2
- 150000005829 chemical entities Chemical class 0.000 abstract 3
- 102000000551 Syk Kinase Human genes 0.000 abstract 2
- 108010016672 Syk Kinase Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- MJHOMTRKVMKCNE-NWDGAFQWSA-N mivavotinib Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=C(F)C2=C1C(=O)NC2 MJHOMTRKVMKCNE-NWDGAFQWSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462093564P | 2014-12-18 | 2014-12-18 | |
| US201562115223P | 2015-02-12 | 2015-02-12 | |
| US201562180222P | 2015-06-16 | 2015-06-16 | |
| PCT/IB2015/002489 WO2016097862A2 (en) | 2014-12-18 | 2015-12-17 | Solid state forms of fused heteroaromatic pyrrolidinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170249A true CR20170249A (es) | 2017-09-25 |
Family
ID=55299676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170249A CR20170249A (es) | 2014-12-18 | 2015-12-17 | Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10676473B2 (OSRAM) |
| EP (2) | EP3233857B1 (OSRAM) |
| JP (3) | JP6778195B2 (OSRAM) |
| KR (1) | KR102037502B1 (OSRAM) |
| CN (1) | CN107108609B (OSRAM) |
| AU (1) | AU2015365580B2 (OSRAM) |
| BR (1) | BR112017013149B1 (OSRAM) |
| CA (1) | CA2970864C (OSRAM) |
| CL (1) | CL2017001561A1 (OSRAM) |
| CO (1) | CO2017005910A2 (OSRAM) |
| CR (1) | CR20170249A (OSRAM) |
| DK (1) | DK3233857T3 (OSRAM) |
| DO (1) | DOP2017000130A (OSRAM) |
| EA (1) | EA032291B1 (OSRAM) |
| EC (1) | ECSP17038100A (OSRAM) |
| ES (1) | ES2788454T3 (OSRAM) |
| GE (1) | GEP20197050B (OSRAM) |
| IL (1) | IL252941B (OSRAM) |
| MX (1) | MX373586B (OSRAM) |
| MY (1) | MY199935A (OSRAM) |
| NZ (1) | NZ732371A (OSRAM) |
| PE (1) | PE20171179A1 (OSRAM) |
| PH (1) | PH12017501123A1 (OSRAM) |
| PL (1) | PL3233857T3 (OSRAM) |
| SG (1) | SG11201701911QA (OSRAM) |
| TN (1) | TN2017000080A1 (OSRAM) |
| UA (1) | UA120632C2 (OSRAM) |
| WO (1) | WO2016097862A2 (OSRAM) |
| ZA (1) | ZA201701800B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3233857T3 (pl) * | 2014-12-18 | 2020-07-27 | Takeda Pharmaceutical Company Limited | Stałe postacie skondensowanych heteroaromatycznych pirolidynonów |
| CA3030630A1 (en) * | 2016-07-13 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
| JP2020537678A (ja) | 2017-10-19 | 2020-12-24 | バイエル・アニマル・ヘルス・ゲーエムベーハー | 動物における疾患の治療および予防のための縮合ヘテロ芳香族ピロリドンの使用 |
| WO2019088039A1 (en) | 2017-10-30 | 2019-05-09 | Takeda Pharmaceutical Company Limited | Treatment of acute myeloid leukemia |
| ES2971892T3 (es) * | 2018-12-14 | 2024-06-10 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Formas cristalinas del inhibidor de Syk sal hidrocloruro de 5-fluoro-1-metil-3-[[5-[4-(3-oxetanil)-1-piperazinil]-2-piridinil]amino]-6-(1H-pirazol-3-il)-2(1H)-quinolinona (1:1) |
| CN113453680A (zh) | 2019-02-07 | 2021-09-28 | 詹森生物科技公司 | 二氢乳清酸脱氢酶抑制剂 |
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| WO2021070132A1 (en) | 2019-10-10 | 2021-04-15 | Janssen Biotech, Inc. | Bi-aryl dihydroorotate dehydrogenase inhibitors |
| AU2020404305A1 (en) | 2019-12-19 | 2022-08-04 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
| WO2022074534A1 (en) | 2020-10-05 | 2022-04-14 | Janssen Biotech, Inc. | Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents |
| WO2022127753A1 (zh) * | 2020-12-18 | 2022-06-23 | 山东轩竹医药科技有限公司 | 稠环类AhR抑制剂 |
| JP2024518497A (ja) | 2021-05-11 | 2024-05-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 併用療法 |
| KR20240006638A (ko) | 2021-05-11 | 2024-01-15 | 얀센 파마슈티카 엔브이 | 조합 요법 |
| CN120322230A (zh) | 2022-11-30 | 2025-07-15 | 詹森药业有限公司 | 包含多发性内分泌癌蛋白-mll抑制剂和至少一种其他治疗剂的组合 |
| WO2024114666A1 (en) | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1960372B1 (en) * | 2005-12-15 | 2015-12-09 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| US8440689B2 (en) | 2009-12-23 | 2013-05-14 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones |
| EP2723739B1 (en) | 2011-06-22 | 2016-08-24 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| TW201625263A (zh) * | 2014-09-24 | 2016-07-16 | 千禧製藥公司 | 利用ＰＩ３Ｋα抑制劑與紫杉烷之組合治療 |
| PL3233857T3 (pl) * | 2014-12-18 | 2020-07-27 | Takeda Pharmaceutical Company Limited | Stałe postacie skondensowanych heteroaromatycznych pirolidynonów |
-
2015
- 2015-12-17 PL PL15831150T patent/PL3233857T3/pl unknown
- 2015-12-17 MY MYPI2017702209A patent/MY199935A/en unknown
- 2015-12-17 PE PE2017000944A patent/PE20171179A1/es unknown
- 2015-12-17 EP EP15831150.6A patent/EP3233857B1/en active Active
- 2015-12-17 CN CN201580068971.2A patent/CN107108609B/zh active Active
- 2015-12-17 TN TN2017000080A patent/TN2017000080A1/en unknown
- 2015-12-17 WO PCT/IB2015/002489 patent/WO2016097862A2/en not_active Ceased
- 2015-12-17 AU AU2015365580A patent/AU2015365580B2/en active Active
- 2015-12-17 BR BR112017013149-8A patent/BR112017013149B1/pt not_active IP Right Cessation
- 2015-12-17 GE GEAP201514545A patent/GEP20197050B/en unknown
- 2015-12-17 EP EP20156863.1A patent/EP3677582B1/en active Active
- 2015-12-17 DK DK15831150.6T patent/DK3233857T3/da active
- 2015-12-17 KR KR1020177019929A patent/KR102037502B1/ko active Active
- 2015-12-17 SG SG11201701911QA patent/SG11201701911QA/en unknown
- 2015-12-17 MX MX2017007162A patent/MX373586B/es active IP Right Grant
- 2015-12-17 NZ NZ732371A patent/NZ732371A/en not_active IP Right Cessation
- 2015-12-17 EA EA201791369A patent/EA032291B1/ru unknown
- 2015-12-17 US US14/973,180 patent/US10676473B2/en active Active
- 2015-12-17 JP JP2017532678A patent/JP6778195B2/ja active Active
- 2015-12-17 ES ES15831150T patent/ES2788454T3/es active Active
- 2015-12-17 CA CA2970864A patent/CA2970864C/en active Active
- 2015-12-17 UA UAA201707489A patent/UA120632C2/uk unknown
- 2015-12-17 CR CR20170249A patent/CR20170249A/es unknown
-
2017
- 2017-03-13 ZA ZA2017/01800A patent/ZA201701800B/en unknown
- 2017-05-31 DO DO2017000130A patent/DOP2017000130A/es unknown
- 2017-06-15 PH PH12017501123A patent/PH12017501123A1/en unknown
- 2017-06-15 CO CONC2017/0005910A patent/CO2017005910A2/es unknown
- 2017-06-15 IL IL252941A patent/IL252941B/en active IP Right Grant
- 2017-06-15 CL CL2017001561A patent/CL2017001561A1/es unknown
- 2017-06-16 EC ECIEPI201738100A patent/ECSP17038100A/es unknown
-
2020
- 2020-04-30 JP JP2020080282A patent/JP6974534B2/ja active Active
- 2020-05-08 US US16/870,653 patent/US11352355B2/en active Active
-
2021
- 2021-11-04 JP JP2021180105A patent/JP2022017477A/ja active Pending
-
2022
- 2022-12-23 US US18/088,286 patent/US20230348461A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20170249A (es) | Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas | |
| MX2021006571A (es) | Inhibidores de tirosina-cinasas. | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| CO2018013803A2 (es) | 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1 | |
| TW201613925A (en) | Imidazopyrazines as LSD1 inhibitors | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| SG10201807952PA (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| EA202191301A1 (ru) | СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| NI201800092A (es) | 1,5-dihidro-4h-pirazolo [3, 4-d] pirimidin-4-onas y 1,5-dihidro-4h-pirazolo [4, 3-c] piridin-4-onas como inhibidores de pde1 | |
| MX391040B (es) | Formulacion de alta concentracion. | |
| CO2019005538A2 (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1 | |
| MX2017000142A (es) | Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. | |
| MX375318B (es) | Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina.. | |
| AR131653A2 (es) | Inhibidores de tirosina quinasa | |
| ECSP18000097A (es) | Inhibidores de tirosina-cinasas |